3 Zimmer Biomet Mobi-C studies featured at French spine meeting: 5 highlights

Megan Wood -   Print  |

Researchers presented three studies on Zimmer Biomet's Mobi-C Cervical Disc at the 2017 French Spine Society Congress, held June 1 to June 3 in Lille.

Here are five highlights:


1. Used to treat cervical total disc replacement, Mobi-C is intended to keep range of motion and flexibility intact after surgery.


2. The three studies illustrate Mobi-C's short- and long-term safety, efficacy and patient satisfaction.


3. One study, "Prevalence, Progression, and Clinical Implications of Heterotopic Ossification after Cervical Disc Arthroplasty at 7 years," found no patients underwent subsequent CTDR due to heterotopic ossification after treatment with the Mobi-C.


4. Another study, "Clinical Results of Cervical Total Disc Replacement with a Self-Adjusting Mobile Core Prosthesis after 10-Year Follow-Up," revealed TDR with a device like Mobi-C was effective and safe.


5. The third study, "Reemergence of Symptoms after Successful Treatment with Cervical Disc Arthroplasty or Anterior Cervical Discectomy and Fusion between 2 to 5 years follow-up," found cervical TDA with Mobi-C treatment was more effective than anterior cervical discectomy and fusion.


More articles on devices:
Vertera Spine raises $3M from 29 investors: 4 key notes
Aurora Spine, DJO Global, Zimmer Biomet & more: 9 device company key notes
Global bone screw system market to see growth through 2027: 6 points

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers